

**EGFR Antibody (Center Q858) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP7628c****Specification**

---

**EGFR Antibody (Center Q858) Blocking Peptide - Product Information**

Primary Accession [P00533](#)  
Other Accession [EGFR\\_HUMAN](#)

**EGFR Antibody (Center Q858) Blocking Peptide - Additional Information**

**Gene ID** 1956

**Other Names**

Epidermal growth factor receptor, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP7628c](/product/products/AP7628c) was selected from the center region with glutamine at the 858th position of human EGFR. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**EGFR Antibody (Center Q858) Blocking Peptide - Protein Information**

**Name** EGFR ([HGNC:3236](#))

**Synonyms** ERBB, ERBB1, HER1

**Function**

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed: [2790960](http://www.uniprot.org/citations/2790960), PubMed: [10805725](http://www.uniprot.org/citations/10805725), PubMed: [27153536](http://www.uniprot.org/citations/27153536)). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed: [2790960](http://www.uniprot.org/citations/2790960), PubMed: [7679104](http://www.uniprot.org/citations/7679104))

target="\_blank">7679104</a>, PubMed:<a href="http://www.uniprot.org/citations/8144591" target="\_blank">8144591</a>, PubMed:<a href="http://www.uniprot.org/citations/9419975" target="\_blank">9419975</a>, PubMed:<a href="http://www.uniprot.org/citations/15611079" target="\_blank">15611079</a>, PubMed:<a href="http://www.uniprot.org/citations/12297049" target="\_blank">12297049</a>, PubMed:<a href="http://www.uniprot.org/citations/27153536" target="\_blank">27153536</a>, PubMed:<a href="http://www.uniprot.org/citations/20837704" target="\_blank">20837704</a>, PubMed:<a href="http://www.uniprot.org/citations/17909029" target="\_blank">17909029</a>). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:<a href="http://www.uniprot.org/citations/27153536" target="\_blank">27153536</a>). May also activate the NF-kappa-B signaling cascade (PubMed:<a href="http://www.uniprot.org/citations/11116146" target="\_blank">11116146</a>). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:<a href="http://www.uniprot.org/citations/11602604" target="\_blank">11602604</a>). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:<a href="http://www.uniprot.org/citations/11483589" target="\_blank">11483589</a>). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:<a href="http://www.uniprot.org/citations/20462955" target="\_blank">20462955</a>). Plays a role in enhancing learning and memory performance (By similarity). Plays a role in mammalian pain signaling (long-lasting hypersensitivity) (By similarity).

### Cellular Location

Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus membrane; Single-pass type I membrane protein. Nucleus membrane; Single-pass type I membrane protein Endosome Endosome membrane. Nucleus. Note=In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:20674546, PubMed:17909029). Endocytosed upon activation by ligand (PubMed:2790960, PubMed:17182860, PubMed:27153536, PubMed:17909029). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055)

### Tissue Location

Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.

## EGFR Antibody (Center Q858) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

## EGFR Antibody (Center Q858) Blocking Peptide - Images

## EGFR Antibody (Center Q858) Blocking Peptide - Background

EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial in maintaining a normal balance in cell growth and development. A prototype member of the type 1 receptor tyrosine kinases, EGFR is encoded by the cellular oncogene *cerbB1*. EGFR has an extracellular ligand binding domain, a single transmembrane region, and cytoplasmic domain which is composed of a tyrosine kinase domain and a carboxy terminal domain. The carboxy terminal domain contains at least four tyrosine autophosphorylation sites. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. EGFR overexpression is

observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

#### **EGFR Antibody (Center Q858) Blocking Peptide - References**

Aifa, S., et al., Exp. Cell Res. 302(1):108-114 (2005). Adams, T.E., et al., Growth Factors 22(2):89-95 (2004). Ichinose, J., et al., Biochem. Biophys. Res. Commun. 324(3):1143-1149 (2004). Kuribayashi, A., et al., Endocrinology 145(11):4976-4984 (2004). Kapoor, G.S., et al., Mol. Cell. Biol. 24(2):823-836 (2004).